Namibia Court Voids Antibiotic Rejection

, Who Judge Orben Sibeya of Namibia’s High Court ruled in a case brought by Econo Investments (Pty) Ltd against the Namibia Medicines Regulatory Council (NMRC)., What The court set aside the NMRC’s rejection of 140,000 vials of Ceftriaxone Sodium for Injection BP 1g, an injectable antibiotic., When The order is dated Thursday, 15 October 2026, two days after the parties settled on 13 October., Buyer The vials were meant for the Central Medical Stores of the Ministry of Health and Social Services, under tender G/DP/1313MS-37/2024.

Namibia’s High Court has set aside the medicines regulator’s rejection of 140,000 vials of an injectable antibiotic meant for the state’s Central Medical Stores. The order, dated 15 October, followed a settlement between the supplier and the regulator.

For US readers, the case shows how legal risk can hold up medicine supply to a small African market. It also matters to exporters, because the vials were bought through a state tender.

Judge Orben Sibeya made a settlement agreement of 13 October a binding order of the court, according to Namibian outlet Observer24. Econo Investments (Pty) Ltd had challenged the Namibia Medicines Regulatory Council (NMRC), the national drug regulator, over its rejection of the vials.

The product is Ceftriaxone Sodium for Injection BP 1g, made by NCPC Hebei Huamin Pharmaceutical, a Chinese manufacturer. It was ordered under tender G/DP/1313MS-37/2024 and purchase order 235388.

Observer24 reports that Econo’s application dates from 2 April 2025, and that an NMRC appeal committee decided on 6 May 2026. Econo argued that the council had to follow that appeal decision when it later rejected the product.

A pharmacist at the Central Medical Stores wrote on 20 September that “given the current stock-out situation for antibiotic items under this contract, expedited submission is needed,” the report says. We could not independently confirm the stock position.

The order sets aside the rejection but, as reported, does not say whether the vials have been imported, paid for or distributed. The settlement terms and the council’s reasons for its decision have not been published.

The court made no order as to costs, and the matter was removed from the roll as finalised. Neither the council nor the Health Ministry has commented in the report we reviewed.

Exporters and investors in African health supply chains should note that a regulator’s rejection can be reversed through court settlement. Procurement timing in Namibia can therefore move with legal outcomes as well as with tenders.

The case involves a Chinese manufacturer and a state buyer, and no US company is named. Exporters selling into state tenders should plan for such disputes.

We have not seen the order or the settlement text, and the story rests on one Namibian news report. The report does not say whether Econo is a Namibian company, and we do not state it.

Whether the product holds a current Namibian registration is not reported. Nor is it clear when the vials will arrive or how the stock-out at the Central Medical Stores will be resolved.

Africa: The New Scramble, why the world’s powers are competing for the continent

Editorial responsibility: Matthias Camenzind , Editor-in-Chief · Editorial standards · Report an error

Judge Orben Sibeya set aside the medicines regulator’s rejection of 140,000 vials of Ceftriaxone Sodium for Injection BP 1g. The order of 15 October 2026 made a settlement of 13 October binding.

Econo Investments (Pty) Ltd was the applicant and the Namibia Medicines Regulatory Council the respondent. The vials were intended for the Ministry of Health’s Central Medical Stores.

Observer24 names NCPC Hebei Huamin Pharmaceutical of China as the maker. The product is an injectable antibiotic used in hospitals.

The report does not say whether the vials have been imported or distributed. The confirmed outcome is limited to the rejection being set aside.